Arcutis Biotherapeutics, Inc. officer Masaru Matsuda filed a Form 144 notice of proposed sale of 1,219 shares of common stock on November 2, 2026, following a restricted stock vesting event on November 1, 2026.

Key Highlights

  • Proposed sale: 1,219 shares of Arcutis Biotherapeutics common stock with an aggregate market value of $38,841.48, according to the filing.
  • Source of shares: The 1,219 shares were acquired on November 1, 2026, through a restricted stock vesting transaction from Arcutis Biotherapeutics.
  • Approximate sale date: The filing lists November 2, 2026 as the approximate date of sale, with Merrill Lynch named as the broker.
  • Shares outstanding: The filing reports 125,691,961 shares of common stock outstanding at the time of the notice.
  • Prior sales: Matsuda sold 9,989 shares on September 8, 2026 for gross proceeds of $249,986.12, and 3,674 shares on September 16, 2026 for gross proceeds of $91,853.24, in the three months preceding this notice.
  • Filer relationship: Masaru Matsuda is identified as an officer of Arcutis Biotherapeutics, Inc. in the filing.

Details of Matsuda's Proposed Common Stock Sale at Arcutis Biotherapeutics

According to the Form 144 filed with the U.S. Securities and Exchange Commission on November 2, 2026, Masaru Matsuda, an officer of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), provided notice of the proposed sale of 1,219 shares of the company's common stock. The filing identifies Merrill Lynch, located at 8890 Lyra Drive, 5th Floor, Columbus, OH 43240, as the named broker for the proposed transaction. The aggregate market value of the shares to be sold is listed as $38,841.48.

The filing discloses that the 1,219 shares were obtained through a restricted stock vesting event on November 1, 2026, with Arcutis Biotherapeutics listed as the person from whom the securities were acquired. The nature of payment is noted as "NA" in the filing, and the transaction is not characterized as a gift. Matsuda's address is listed as 3027 Townsgate Rd Suite 300, Westlake Village, CA 91361, which matches the issuer's address on record.

The filing also discloses Matsuda's common stock sales during the three months prior to this notice. On September 8, 2026, Matsuda sold 9,989 shares for gross proceeds of $249,986.12, and on September 16, 2026, an additional 3,674 shares were sold for gross proceeds of $91,853.24. The notice is dated November 2, 2026, and bears Matsuda's signature in accordance with Rule 144 under the Securities Act of 1933.

What Was Disclosed

Arcutis Biotherapeutics officer Masaru Matsuda filed a Form 144 on November 2, 2026, disclosing a proposed sale of 1,219 shares valued at $38,841.48, acquired through restricted stock vesting on November 1, 2026, along with two prior common stock sales totaling 13,663 shares in September 2026.